RT Journal Article
SR Electronic
T1 A Streamlined CyTOF Workflow To Facilitate Standardized Multi-Site Immune Profiling of COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.26.20141341
DO 10.1101/2020.06.26.20141341
A1 Geanon, Daniel
A1 Lee, Brian
A1 Kelly, Geoffrey
A1 Handler, Diana
A1 Upadhyaya, Bhaskar
A1 Leech, John
A1 Herbinet, Manon
A1 Valle, Diane Del
A1 Gnjatic, Sacha
A1 Kim-Schulze, Seunghee
A1 Merad, Miriam
A1 Rahman, Adeeb H.
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.26.20141341.abstract
AB Mass cytometry (CyTOF) represents one of the most powerful tools in immune phenotyping, allowing high throughput quantification of over 40 single parameters at single-cell resolution. However, wide deployment of CyTOF-based immune phenotyping studies are limited by complex experimental workflows and the need for specialized CyTOF equipment and technical expertise. Furthermore, differences in cell isolation and enrichment protocols, antibody reagent preparation, sample staining and data acquisition protocols can all introduce technical variation that can potentially confound integrative analyses of large data-sets of samples processed across multiple labs.Here, we describe the validation of a streamlined whole blood CyTOF workflow that addresses many of these challenges and facilitates wider adoption of CyTOF immune monitoring across sites with limited technical expertise or sample-processing resources or equipment. Our workflow utilizes commercially available reagents including the Fluidigm MaxPar Direct Immune Profiling Assay, a dry tube 30-marker immunophenotyping panel, and SmartTube Proteomic Stabilizer, which allows for simple and reliable fixation and cryopreservation of whole blood samples. We validate a workflow that allows for streamlined staining of whole blood samples with minimal processing requirements or expertise at the site of sample collection, followed by shipment to a central CyTOF core facility for batched downstream processing and data acquisition. We further demonstrate the application of this workflow to characterize immune responses in a cohort of hospitalized COVID-19 patients, highlighting key disease-associated changes in immune cell frequency and phenotype.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH U19AI118610, U24AI118644 and U24CA224319. Helios mass cytometry instrumentation at the Human Immune Monitoring Center was obtained with support from S10OD023547.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected from consented healthy donors and hospitalized COVID-19 patients under protocols approved by the Mount Sinai Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnnotated FCS files have been deposited in FLOWRepository under IDs: FR-FCM-Z2XA and FR-FCM-Z2XB